Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT00635193

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

A Phase 1/2, Open-Label, Adaptive, Randomized Study of Liposomal Doxorubicin With or Without M200 (Volociximab) for the Treatment of Subjects With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer That Have Relapsed After Prior Therapy With a Platinum/Taxane-Based Chemotherapy

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Ovarian Cancer, Primary Peritoneal Cancer

Interventions Liposomal Doxorubicin M200 (Volociximab)

Updated 8 times since 2017 Last updated: Jan 10, 2013 Started: Jul 31, 2007 Primary completion: Oct 31, 2008 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Ovarian Cancer, Primary Peritoneal Cancer and is currently completed. AbbVie (prior sponsor, Abbott) leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie (prior sponsor, Abbott)
Biogen

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Antwerp, Belgium , Atlanta, United States , Baltimore, United States , Barcelona, Spain , Bellinzona, Switzerland , Bialystok, Poland , Brussels, Belgium , Corpus Christi, United States , Dallas, United States and 24 more locations